Dr. Joel Braunstein of C2N Diagnostics will discuss development of accurate, simple, lower-cost and widely accessible blood-based tests to improve the diagnostic evaluation of patients with memory impairments and at risk for Alzheimer’s Disease using high-resolution mass spectrometry based multi-analyte assays, based on the clinically available PrecivityAD™ test (amyloid beta 42 and 40 peptides) and newly available P-tau multi-analyte assay.

For General Laboratory Use Only. Not for use in diagnostic procedures.

About the presenter

Dr. Joel Braunstein, CEO, C2N Diagnostics

Dr. Joel Braunstein, CEO, C2N Diagnostics

Dr. Braunstein is Co-Founder and CEO of C2N Diagnostics, a molecular diagnostics and therapeutics company spun out of the neuroscience laboratories of Drs. David Holtzman and Randall Bateman at the Washington University School of Medicine, St. Louis, Missouri. Dr. Braunstein has played a senior executive role in numerous emerging life sciences companies since 2004. He received his M.D. with Highest Distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School, and was a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions.

 
Register to view the free on-demand webinar

* Required field

Resources

 

Style Sheet for Global Design System
CMD Wide-format style fixes